# VBC103

Source: https://onco.cc/drugs/vbc103/  
OnCo record `vbc103` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VBC103 is an experimental drug designed to recognize two proteins on cancer cells. Its early trial is testing safety and activity.

## Summary

NCT07299747 registers a first-in-human phase I/IIa study of VBC103 targeting Nectin-4 and TROP2. It includes dose escalation, dose optimization and cohort expansion in advanced solid tumors. The registry names VelaVigo Bio Inc as sponsor. No tabular results are posted. Payload identity and comparative clinical efficacy are not inferred from the public registry.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: ADC
- Mechanism: Bispecific antibody-drug conjugate targeting Nectin-4 and TROP2, as described in the registered trial title.

## Sources

- ClinicalTrials.gov NCT07299747: https://clinicaltrials.gov/study/NCT07299747

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/), [TROP2](https://onco.cc/targets/trop2/)
- trials: [Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07299747/)

---
JSON: https://onco.cc/api/v1/entities/vbc103.json